EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Low-dose warfarin with a novel mechanical aortic valve: Interim registry results at 5-year follow-up

Marc W Gerdisch, Robert Carl Hagberg, Michael J Perchinsky, Mark Joseph, Aung Y Oo, Mahmoud Loubani, Geoffrey M Tsang, Joseph Zacharias, Mohanakrishnan Sathyamoorthy

The Journal of Thoracic and Cardiovascular Surgery · 2024

DOI: 10.1016/j.jtcvs.2024.04.017 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2024. Verfasst von Marc W Gerdisch und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, Franciscan Health, Indianapolis, Ind. Electronic address: mgerdisch@openheart.net. Hauptthemen laut MEDLINE: Warfarin, Registries, Heart Valve Prosthesis, Anticoagulants. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To evaluate whether warfarin targeted at an international normalized ratio of 1.8 (range, 1.5-2.0) after On-X mechanical aortic valve implant is safe for all patients. METHODS: This prospective, observational clinical registry assessed adverse event rates in adult patients receiving low-dose warfarin (target international normalized ratio, 1.8; range, 1.5-2.0) plus daily aspirin (75-100 mg) during a 5-year period after On-X aortic valve implant. The primary end point is the combined rate of major bleeding, valve thrombosis, and thromboembolism overall and in 4 subgroups. The comparator is the Prospective Randomized On-X Anticoagulation Trial control group patients on standard-dose warfarin (international normalized ratio, 2.0-3.0) plus aspirin 81 milligrams daily. RESULTS: A total of 510 patients were recruited at 23 centers in the United States, United Kingdom, and Canada between November 2015 and January 2022. This interim analysis includes 229 patients scheduled to complete 5-year follow-up by August 16, 2023. The linearized occurrence rate (in percent per patient-year) of the primary composite end point of major bleeding, valve thrombosis, and thromboembolism is 1.83% compared with 5.39% (95% confidence interval, 4.12%-6.93%) in the comparator group. Results are consistent in clinic-monitored and home-monitored patients and in those at high risk for thromboembolism. Major bleeding and total bleeding were reduced by 87% and 71%, respectively, versus the comparator group, without an increase in thromboembolic events. CONCLUSIONS: Interim results support the continued safety of the On-X aortic mechanical valve with a target international normalized ratio of 1.8 plus low-dose aspirin through 5 years after implant, with or without home monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

WarfarinRegistriesHeart Valve ProsthesisAnticoagulantsAortic ValveThromboembolismHemorrhageThrombosisInternational Normalized RatioHumansMaleFemaleProspective StudiesAgedMiddle AgedHeart Valve Prosthesis ImplantationAspirinTreatment OutcomeTime FactorsAged, 80 and overRisk FactorsProsthesis Design

Stichwörter der Autor:innen

anticoagulationaortic valve replacementlow-dose warfarinmechanical heart valveprosthetic valve

Substanzen

WarfarinAnticoagulantsAspirin

Autor:innen und Institutionen

  • Department of Cardiothoracic Surgery, Franciscan Health, Indianapolis, Ind. Electronic address: mgerdisch@openheart.net.
  • Department of Cardiac Surgery, Hartford Hospital, Hartford, Conn.
  • Department of Surgery, Royal Jubilee Hospital, Victoria, British Columbia, Canada.
  • Department of Surgery, Virginia Tech Carilion School of Medicine, Roanoke, Va.
  • Department of Cardiovascular Surgery, Bart's Health NHS Trust, London, United Kingdom.
  • Department of Cardiothoracic Surgery, Hull University Teaching Hospitals NHS Trust, Hull, United Kingdom.

Zitieren

APA

Gerdisch, M. W., Hagberg, R. C., Perchinsky, M. J., Joseph, M., Oo, A. Y., Loubani, M., Tsang, G. M., Zacharias, J., & Sathyamoorthy, M. (2024). Low-dose warfarin with a novel mechanical aortic valve: Interim registry results at 5-year follow-up. The Journal of Thoracic and Cardiovascular Surgery. https://doi.org/10.1016/j.jtcvs.2024.04.017

Vancouver

Gerdisch MW, Hagberg RC, Perchinsky MJ, Joseph M, Oo AY, Loubani M, et al. Low-dose warfarin with a novel mechanical aortic valve: Interim registry results at 5-year follow-up. The Journal of Thoracic and Cardiovascular Surgery. 2024. doi:10.1016/j.jtcvs.2024.04.017

BibTeX
@article{Gerdisch2024,
  author = {Gerdisch, Marc W and Hagberg, Robert Carl and Perchinsky, Michael J and Joseph, Mark and Oo, Aung Y and Loubani, Mahmoud and Tsang, Geoffrey M and Zacharias, Joseph and Sathyamoorthy, Mohanakrishnan},
  title = {Low-dose warfarin with a novel mechanical aortic valve: Interim registry results at 5-year follow-up},
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  year = {2024},
  doi = {10.1016/j.jtcvs.2024.04.017}
}
Kostenlos starten →